Tristel (TSTL) Competitors

NIOX Group has lower revenue, but higher earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Tristel has a beta of 0.346, meaning that its share price is 65% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

NIOX Group has a consensus target price of GBX 86, suggesting a potential upside of 32.63%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts plainly believe NIOX Group is more favorable than Tristel.

Tristel has a net margin of 15.88% compared to NIOX Group's net margin of 14.37%. Tristel's return on equity of 23.64% beat NIOX Group's return on equity.

In the previous week, Tristel's average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

22.5% of Tristel shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Comparatively, 5.1% of NIOX Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.4%. NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 1.9%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Tristel has a net margin of 15.88% compared to EKF Diagnostics' net margin of 4.12%. Tristel's return on equity of 23.64% beat EKF Diagnostics' return on equity.

Tristel has a beta of 0.346, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

In the previous week, EKF Diagnostics had 1 more articles in the media than Tristel. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Tristel. Tristel's average media sentiment score of 0.00 equaled EKF Diagnostics'average media sentiment score.

22.5% of Tristel shares are owned by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 40.0% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

EKF Diagnostics has a consensus price target of GBX 35, suggesting a potential upside of 38.34%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe EKF Diagnostics is more favorable than Tristel.

Tristel has higher earnings, but lower revenue than EKF Diagnostics. Tristel is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Tristel's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

22.5% of Tristel shares are held by institutional investors. Comparatively, 0.7% of INSPECS Group shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Comparatively, 19.6% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Tristel has a beta of 0.346, suggesting that its share price is 65% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, suggesting that its share price is 61% more volatile than the broader market.

INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 36.17%. Given INSPECS Group's stronger consensus rating and higher possible upside, analysts plainly believe INSPECS Group is more favorable than Tristel.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Creo Medical Group has a net margin of 88.33% compared to Tristel's net margin of 15.88%. Tristel's return on equity of 23.64% beat Creo Medical Group's return on equity.

In the previous week, Tristel's average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Tristel has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Tristel has a beta of 0.346, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, indicating that its stock price is 56% more volatile than the broader market.

22.5% of Tristel shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 21.0% of Tristel shares are held by company insiders. Comparatively, 7.0% of Creo Medical Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.